Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening (SPIT-LC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00607425|
Recruitment Status : Terminated (Change in isolation method)
First Posted : February 5, 2008
Last Update Posted : July 17, 2008
This is a pilot study to test the feasibility of using gene expression from saliva to identify patients with early-stage non-small cell lung cancer (NSCLC).
The primary objective of this study is to compare gene expression profiles from saliva from healthy controls and patients with early-stage non-small cell lung cancer.
To be eligible, patients with non-small cell lung cancer, must not yet have received treatment for their cancer (surgical removal, chemotherapy, or radiation therapy). Health control participants may participate if they meet eligibility criteria listed below.
Eligible enrollees will be asked to submit a one time saliva sample and complete a study questionaire.
|Condition or disease|
|Non-Small Cell Lung Cancer|
|Study Type :||Observational|
|Actual Enrollment :||40 participants|
|Official Title:||Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening|
|Study Start Date :||August 2007|
|Actual Primary Completion Date :||July 2008|
|Actual Study Completion Date :||July 2008|
Non-small cell lung cancer patients
Healthy control subjects
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00607425
|Principal Investigator:||Glen J Weiss, MD||TGen Clinical Research Services at Scottsdale Healthcare|